Authors : Michalis Iosifidis

Volume/Issue : Volume 9 - 2024, Issue 11 - November

Google Scholar : https://tinyurl.com/chbrrmy9

Scribd : https://tinyurl.com/4bx3m4z4

DOI : https://doi.org/10.5281/zenodo.14436458

Abstract : Prostate cancer is the second commonest malignancy in men worldwide and disease incidence increases with increasing age. Prognosis is affected by different variables but it is well established that Prostate cancer is a slow growing/spreading malignancy and thus resulting in a high prevalence. Brachytherapy, permanent radioactive seed implantation, remains an invaluable therapy for organ confined disease with high disease free survival (66-79%). When compared with radical prostatectomy, brachytherapy is perceived as a safer option for co-morbid patients, that have a higher anaesthetic risk. Having said that, rectourethral fistula as a complication of radiation proctitis is a well established risk that can result in significant morbidity and negatively impact in patients quality of life.

Keywords : Morbidity, Rectourethral Fistula, Catheter, Brachytherapy, Prostate Cancer.

References :

1. Rawla, P., 2019. Epidemiology of prostate cancer. World journal of oncology, 10(2), p.63.
2. Panigrahi, G.K., Praharaj, P.P., Kittaka, H., Mridha, A.R., Black, O.M., Singh, R., Mercer, R., van Bokhoven, A., Torkko, K.C., Agarwal, C. and Agarwal, R., 2019. Exosome proteomic analyses identify inflammatory phenotype and novel biomarkers in African American prostate cancer patients. Cancer medicine, 8(3), pp.1110-1123.
3. Ragde, H., Grado, G.L., Nadir, B. and Elgamal, A.A., 2000. Modern prostate brachytherapy. CA: A Cancer Journal for Clinicians, 50(6), pp.380-393.
4. Schlussel Markovic, E., Buckstein, M., Stone, N.N. and Stock, R.G., 2018. Outcomes and toxicities in patients with intermediate‐risk prostate cancer treated with brachytherapy alone or brachytherapy and supplemental external beam radiation therapy. BJU international, 121(5), pp.774-780.
5. Sanda, M.G., Dunn, R.L., Michalski, J., Sandler, H.M., Northouse, L., Hembroff, L., Lin, X., Greenfield, T.K., Litwin, M.S., Saigal, C.S. and Mahadevan, A., 2008. Quality of life and satisfaction with outcome among prostate-cancer survivors. New England Journal of Medicine, 358(12), pp.1250-1261.
6. Giberti, C., Gallo, F., Schenone, M., Gastaldi, E., Cortese, P., Ninotta, G. and Becco, D., 2017. Robotic prostatectomy versus brachytherapy for the treatment of low risk prostate cancer. Can J Urol, 24(2), pp.8728-8733.
7. Morris, W.J., Keyes, M., Spadinger, I., Kwan, W., Liu, M., McKenzie, M., Pai, H., Pickles, T. and Tyldesley, S., 2013. Population‐based 10‐year oncologic outcomes after low‐dose‐rate brachytherapy for low‐risk and intermediate‐risk prostate cancer. Cancer, 119(8), pp.1537-1546.
8. Chargari, C., Deutsch, E., Blanchard, P., Gouy, S., Martelli, H., Guérin, F., Dumas, I., Bossi, A., Morice, P., Viswanathan, A.N. and Haie‐Meder, C., 2019. Brachytherapy: An overview for clinicians. CA: a cancer journal for clinicians, 69(5), pp.386-401.
9. Eccles, B.K., Cross, W., Rosario, D.J., Doble, A., Parker, C., Logue, J., Little, L., Stanton, L. and Bottomley, D., 2013. SABRE 1 (S urgery A gainst B rachytherapy–a R andomised E valuation): feasibility randomised controlled trial (RCT) of brachytherapy vs radical prostatectomy in low–intermediate risk clinically localised prostate cancer. BJU international, 112(3), pp.330-337.
10. García-Sánchez, C., Román Martín, A.A., Conde-Sánchez, J.M., Congregado-Ruíz, C.B., Osman-García, I. and Medina-López, R.A., 2017. Comparative analysis of short-term functional outcomes and quality of life in a prospective series of brachytherapy and Da Vinci robotic prostatectomy. International braz j urol, 43, pp.216-223.
11. Marguet, C., Raj, G.V., Brashears, J.H., Anscher, M.S., Ludwig, K., Mouraviev, V., Robertson, C.N. and Polascik, T.J., 2007. Rectourethral fistula after combination radiotherapy for prostate cancer. Urology, 69(5), pp.898-901.